Synageva BioPharma Corp. (“Synageva”) GEVA, a clinical
stage biopharmaceutical company developing therapeutic products for rare
disorders, today announced that it has commenced a $80 million
underwritten public offering of shares of its common stock. In
connection with this offering, Synageva expects to grant to the
underwriters a 30-day option to purchase additional shares of common
stock, equal to up to 15% of the number of shares of common stock sold
in the offering. Morgan Stanley and J.P. Morgan are acting as joint
book-running managers in the offering, and Cowen and Company is acting
as co-manager in the offering.
The securities described above are being offered by Synageva pursuant to
a Form S-3 shelf registration
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in